Analyst Conference Summaries

Biotechnology Investor Aids

Juno Therapeutics
JUNO

conference date: November 1, 2017 @ 2:00 PM Pacific Time

Since Juno has been bought by Celgene, there will be no further coverage.

See Celgene to Acquire Juno Therapeutics

Juno Therapeutics: Celgene Partnership and CAR-T Pipeline Value [Sept. 9, 2015]

June Therapeutics Reports Q2 2015 Results [August 12, 2015]

2017
May 4, 2017
August 3, 3017
Nov. 1, 2017
 
2016
05/09/2016
08/04/2016
11/09/2016
03/01/2017
2015
JUNO
Q1
not available
 JUNO
Q2
not available
08/12/2015
11/10/2015
02/29/2016 

Juno Therapeutics (JUNO) is a clinical development stage biotechnology company specializing in immunotherapy.

Juno Therapeutics web site


 

Search

More Analyst Conference Pages:

 AGEN
 AGIO
 ALNY
 ALXN
 AMAT
 AMD
 AMGN
 BIIB
 CLDX
 CELG
 EPZM
 GILD
 GLYC
 INO
 INTC
 ISRG
 JUNO
 MACK
 MCHP
 MYL.
 NVDA
 PLX
 REGN
 SGEN
 XLNX
 XLRN

 

Disclaimer: Our analyst summaries may include both our condensations of statements made by company representatives and our own analysis. They are not covered by any warranty. We cannot guarantee anything said by company representatives is true. We try not to make errors, but it is possible. This is investment journalism, not financial advice.

Copyright 2015 William P. Meyers